Evidence map›Paper›PMID 41912590›Full record

ArticleNPJ vaccines2026

IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner.

Yuya Yoshioka, Anri Nishinaka-Yoshioka, Kouji Kobiyama, Tomoya Hayashi, Yujiro Kidani, Yosuke Yanagida, Junpei Kasahara, Kenichiro Tsujii, Yoshiji Asaoka, Norikazu Kuroda and 10 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yuya Yoshioka *Vaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Anri Nishinaka-Yoshioka *Vaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Kouji KobiyamaDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Tokyo, Japan.
Tomoya HayashiDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Tokyo, Japan.
Yujiro KidaniVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Yosuke YanagidaVaccine Manufacturing Technology Research Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Junpei KasaharaVaccine Manufacturing Technology Research Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Kenichiro TsujiiVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Yoshiji AsaokaLaboratory for Drug Discovery and Development, Shionogi & Co. Ltd., Osaka, Japan.
Norikazu KurodaLaboratory for Medicinal Chemistry Research, Shionogi & Co. Ltd., Osaka, Japan.
Akira KugimiyaLaboratory for Medicinal Chemistry Research, Shionogi & Co. Ltd., Osaka, Japan.
Hiroaki OsawaVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Akimasa YoshimuraVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Motoyasu OnishiLaboratory for Drug Discovery and Disease Research, Shionogi & Co. Ltd., Osaka, Japan.
Takayuki NakagawaVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Satoru IshidaVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Shinya OmotoVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Morio NagiraVaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.
Cevayir CobanDivision of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Tokyo, Japan.
Ken J IshiiDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Tokyo, Japan. kenishii@ims.u-tokyo.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squalene-based adjuvants are widely utilized in various vaccines because of their effectiveness in enhancing immune responses. Among these, A-910823 and AS03 are recognized squalene-based adjuvants containing α-tocopherol. Although α-tocopherol-containing squalene-based adjuvants are known to enhance humoral immune responses and inflammatory cytokine production, their underlying mechanisms remain unclear. Here, we found that A-910823 regulated IL-1 signaling pathway gene expression and IL-1α and IL-1β protein expressions in an α-tocopherol-dependent manner. While the source of IL-1α was mainly from eosinophils, IL-1β was from a wide range of myeloid cells. Mechanistically, IL-1β/CD11c

Identifiers

PMID41912590
PMCPMC13036020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.